– DENMARK, Ballerup – Saniona (OMX: SANION), a biotech company focused on the treatment of eating disorders and diseases of the central nervous system, today announced that its Nomination Committee has proposed Edward C. Saltzman as new member of the Board of Directors.
The company’s shareholders will resolve on this nomination at the Annual General Meeting to be held on May 29, 2019.
“We are extremely pleased to be nominating Ed Saltzman as a new Board member,” said J. Donald deBethizy, Saniona’s Chairman of the Board. “Ed’s extensive strategic and commercial experience within rapidly growing biotechnology companies is a great addition to our Board as we continue to build Saniona’s pipeline of innovative drug candidates. This appointment adds to the existing expertise of our highly-respected Board members as they guide Saniona toward continued growth and success.”
About Ed Saltzman
Edward C. Saltzman is Executive Chairman of Cello Health BioConsulting (CHBC), previously Defined Health, after having led the sale of Defined Health to Cello Health in 2017. CHBC is a leading strategic business development advisory firm serving senior executives in pharma, biotech, and investment. Edward C. Saltzman possesses a vast knowledge of the pharmaceutical and biotechnology industry accumulated over Defined Health’s 25+ years of consultancy to pharma, biotech, specialty pharma, and investors. From this breadth and depth of experience, he provides guidance to CHBC’s senior project leadership who work with clients across multiple therapeutic areas. Edward C. Saltzman is a well-regarded and in-demand speaker on industry issues and has been recognized widely as an early “spotter” of key trends that go on to have significant impact within the life sciences industry, especially as these pertain to the licensing and business development field.
Edward C. Saltzman previous experience includes positions at the Ayerst Laboratories unit of American Home Products, where he had responsibility for evaluation and forecasting of compounds being considered for licensing, and at FIND/SVP, where he managed the Healthcare Information Center.
Other current positions: Edward C. Saltzman serves as a Venture Advisor to the Israel Biotech Fund and is a board member of Vidac Pharma.
About Saniona
Saniona is a research and development company focused on drugs for diseases of the central nervous system and eating disorders. The company has five programs in clinical development. Saniona intends to develop and commercialize treatments for orphan indications such as Prader-Willi syndrome and hypothalamic obesity on its own. The research is focused on ion channels and the company has a broad portfolio of research programs. Saniona has partnerships with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, and the company’s shares are listed at Nasdaq Stockholm Small Cap (OMX: SANION).
For more information: https://saniona.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
